10/18/2026
https://www.facebook.com/share/19CiFXcZ8u/?mibextid=wwXIfr
A paper published in the Journal of Orthomolecular Medicine is exploring an unconventional approach to cancer treatment that combines existing medications, nutritional strategies, and metabolic interventions to target cancer cells through multiple pathways.
Titled “Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol,” the paper's authors include Dr. Paul Marik, Ilyes Baghli, William Makis, Pierrick Martinez, and other collaborators.
The proposed protocol explores repurposed medications, including ivermectin, mebendazole, and fenbendazole, alongside vitamins, dietary interventions, and strategies aimed at cancer metabolism, mitochondrial function, and cancer stem cells.
The underlying idea is that cancer may be approached not only by targeting genetic changes in tumor cells, but also by investigating how cancer cells use energy, survive treatment, and contribute to disease progression.
Instead of developing entirely new medicines from scratch, researchers are investigating whether existing medications, already known in other medical contexts, may have overlooked anti-cancer properties.
The next important step would be rigorous human studies to determine whether these approaches actually improve outcomes for patients.
There is also a legitimate conversation to be had about research funding and commercial incentives. Inexpensive medicines may offer less financial incentive for some companies to develop, and that's why little research is done to find out what else may work. But these forward thinking doctors are pushing the envelope on the subject.
